Introduction {#Sec1}
============

Acute kidney injury (AKI) occurs commonly in the ICU and is associated with substantial morbidity and mortality \[[@CR1]-[@CR6]\]. Continuous renal replacement therapy (CRRT) is a preferred choice for critically ill patients, especially when they are hemodynamically unstable. However, despite improvements in CRRT techniques and the general management of critically ill patients, the mortality of patients who require CRRT remains high at more than 40% \[[@CR7]-[@CR9]\].

A decade ago, CRRT intensity as high as 35 mL/kg/h was recommended for critically ill patients with AKI to improve mortality \[[@CR10]\]. However, more recently, two large randomized controlled trials have shown that there is no advantage to high intensity CRRT (\>35 mL/kg/h) with regard to hospital mortality \[[@CR7],[@CR9]\]. Based on these results, 20 or 25 mL/kg/h has been recommended as the lower limit of intensity during CRRT by the recent KDIGO (Kidney Disease Improving Global Outcomes) Clinical Practice Guideline \[[@CR11]\]. However, limited information is available to support this threshold and an optimal CRRT intensity for AKI remains unknown \[[@CR12]-[@CR17]\]. Because the one of the aims of providing CRRT to critically ill patients is to control uremia, very low intensity during CRRT may not be acceptable if low molecular weight solutes (for example, creatinine and urea) increase during the procedure \[[@CR18]\].

Previously, no studies have focused on the lower limit of intensity sufficient to control uremia during CRRT \[[@CR19]\]. The Japanese Society of Education for Physicians and Trainees in Intensive Care (JSEPTIC) CRRT database is a multicenter retrospective study that aims to understand multiple aspects of CRRT \[[@CR13],[@CR20]\]. As part of the larger study, we aimed to evaluate the impact of different intensities of CRRT on the clearance of creatinine and urea in critically ill patients with severe AKI.

Materials and methods {#Sec2}
=====================

This is a multicenter retrospective study that was conducted in 14 ICUs in 12 centers in Japan. The study protocol was reviewed and approved by the Ethics Committee or Investigational Review Board of each participating center. Ethics Committees in all centers waived the need for written informed consent because data were collected retrospectively.

Study population {#Sec3}
----------------

All patients older than 18 years admitted to one of the participating ICUs between January and December 2010 and treated with CRRT due to AKI according to the risk, injury, failure, loss, end-stage renal failure (RIFLE) criteria \[[@CR21]\] were eligible. The following patients were excluded from this study: patients aged less than 18 years, patients with any renal replacement therapy (RRT) before ICU admission, and patients with end-stage renal failure on chronic dialysis. Patients with no information on their body weight at ICU admission were also excluded because their CRRT intensity could not be calculated. If a patient was admitted to the ICU and treated with CRRT more than once during the same hospital admission, only the first ICU admission was included.

Data collection {#Sec4}
---------------

The following data were obtained from case report forms: age, gender, body weight (measured or estimated at ICU admission based on the methods of each participating center), date of hospital admission, date of ICU admission, simplified acute physiology score (SAPS II) on the day of ICU admission \[[@CR22]\] and primary diagnosis. Factors contributing to AKI were collected and categorized according to the following list: septic shock, major surgery, cardiogenic shock, hypovolemia, drug-induced, or other. Multiple choices were allowed if necessary. The following data were also collected at CRRT initiation: use of vasopressors and mechanical ventilation, mean arterial pressure (MAP), arterial partial pressure of oxygen/inspired oxygen fraction (PaO~2~/FiO~2~) ratio, lactate, Glasgow coma scale (GCS), platelet count, bilirubin, diuretic use, urine output, CRRT mode (continuous veno-venous hemofiltration (CVVH), continuous veno-venous hemodialysis (CVVHD), continuous veno-venous hemodiafiltration (CVVHDF)), and blood flow rate. Serum creatinine and urea levels were collected at CRRT initiation (day 1) and over the first 7 days of CRRT. Dates and times of CRRT start and stop, and dialysate and replacement flow rates were collected for each filter over the first 7 days of CRRT. The CRRT dose was defined as the sum of the dialysate and replacement flow rates (mL/h) because all CVVH and CVVHDF were performed with post-dilution. The CRRT intensity was defined as the CRRT dose divided by body weight (mL/kg/h). ICU and hospital mortality and RRT requirement at hospital discharge were also collected.

Definitions for CRRT intensity and creatinine/urea change {#Sec5}
---------------------------------------------------------

As this is a retrospective study, the CRRT dose was decided by treating physicians and could have changed every day according to patient conditions. We therefore evaluated the effect of CRRT intensity by two different definitions: daily intensity and average intensity. Daily intensity was defined as the mean intensity over each 24-h period (from 6:00 AM to 6:00 AM next day). For example, if CRRT was performed at 15 mL/kg/h for 4 h and also at 10 mL/kg/h for 10 h in one day (with a period of 10 h with no CRRT), the daily intensity was calculated as:$$\documentclass[12pt]{minimal}
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Average intensity was defined as the mean of daily intensity during the period while CRRT was performed in the ICU.

Relative and daily creatinine/urea changes were calculated as follows:$$\documentclass[12pt]{minimal}
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where C~day\ N~ is the concentration of creatinine or urea on day N and C~day\ N+1~ is the concentration of creatinine on the next day.

Statistical analyses {#Sec6}
--------------------

Data are presented as medians and interquartile ranges (25^th^ to 75^th^ percentiles) or percentages. To study the effect of different CRRT intensities on clearance of urea and creatinine, all patients/daily observations were arbitrarily allocated to one of four groups based on the average intensity (patients) and daily intensity (daily observations): \<10, 10 to 15, 15 to 20, and \>20 mL/kg/h. The Chi-square test was used for nominal variables and the Kruskal-Wallis test was used for numerical variables to compare differences among the four intensity groups. All tests were two-tailed, and *P*-values \<0.05 were considered statistically significant. All statistical analyses were performed using a commercially available statistical package, JMP 10.0 (SAS Inc., Cary, NC, USA).

Results {#Sec7}
=======

During the study period, a total of 343 patients were registered into the JSEPTIC database. Of these, 27 were excluded because information on their body weight at ICU admission and creatinine (or urea) one day after starting CRRT (needed to calculate the daily intensity and relative creatinine/urea changes) were not collected. The remaining 316 patients were divided into four groups according to the average CRRT intensity (\<10, 10 to 15, 15 to 20, and \>20). The groups comprised 64 (20.3%), 138 (43.7%), 68 (21.5%), and 46 patients (14.6%), respectively. Patient demographics are shown in Table [1](#Tab1){ref-type="table"}. The SAPS II score increased (46 in the \<10 group and 63 in the \>20 group; *P* =0.02) and body weight decreased (68 kg in the \<10 group and 50 kg in the \>20 group; *P* \<0.0001) as the average intensity increased. Septic shock was more common in the groups exhibiting a higher CRRT intensity, and major surgery and cardiogenic shock were more common in the groups exhibiting a lower CRRT intensity.Table 1**Patient demographicsAverage intensity, mL/kg/h\<10 (n =64)10 to 15 (n =138)15 to 20 (n =68)\>20 (n =46)*P*** **-value**Age, years67 (53, 76)69 (60, 76)71 (58, 79)71 (60, 77)0.31Gender, male47 (73.4%)93 (67.4%)45 (66.2%)22 (47.8%)0.04Weight, kg68 (60, 79)60 (52, 70)54 (50, 61)50 (42, 60)\<0.0001SAPS II score49 (37, 65)52 (39, 64)52 (39, 68)63 (50, 79)0.02Premorbid creatinine, μmol/L95 (70, 137)93 (68, 177)88 (68, 157)74 (55, 105)0.17Postoperative admission17 (26.6%)48 (34.8%)29 (42.7%)5 (10.9%)0.002Diagnostic grouping  Cardiovascular33 (51.6%)65 (47.1%)26 (38.2%)9 (19.6%)0.003  Gastrointestinal12 (18.8%)34 (24.6%)15 (22.1%)12 (26.1%)0.77  Sepsis7 (10.9%)13 (9.4%)11 (16.2%)3 (6.5%)0.36  Respiratory8 (12.5%)18 (13.0%)11 (16.2%)8 (17.4%)0.83  Others18 (28.1%)32 (23.2%)21 (30.9%)20 (43.5%)0.28Contributing factors to AKI  Septic shock22 (34.4%)66 (47.8%)37 (54.4%)26 (56.5%)0.07  Major surgery20 (31.3%)35 (25.4%)17 (25.0%)3 (6.5%)0.02  Cardiogenic shock28 (43.8%)40 (29.0%)10 (14.7%)7 (15.2%)0.0005  Hypovolemia11 (17.2%)26 (18.8%)20 (29.4%)14 (30.4%)0.13  Drugs1 (1.6%)7 (5.1%)6 (8.8%)5 (10.9%)0.15  Others10 (15.6%)15 (10.9%)11 (16.2%)13 (28.3%)0.09Results are presented as median (IQR) or number (%). n, number of patients; SAPS II, simplified acute physiology score II; AKI, acute kidney injury.

Table [2](#Tab2){ref-type="table"} shows the patient characteristics at CRRT initiation and the outcomes in the four groups. There were no significant differences in vital signs and laboratory data (vasopressor use, MAP, mechanical ventilation, PaO~2~/FiO~2~ ratio, lactate, GCS, platelet count, bilirubin, urine output, creatinine, and urea) between the four groups. The rate of diuretic use increased as the average intensity decreased (56.3% in the \<10 group and 28.3% in the \>20 group; *P* =0.035). There was a significant difference in CRRT dose (0.60 L/h in the \<10 group and 1.3 L/h in the \>20 group; *P* \<0.0001) and average intensity (8.7 mL/kg/h in the \<10 group and 24.4 mL/kg/h in the \>20 group; *P* \<0.0001) between the four groups. ICU and hospital mortality were similar among the four groups (*P* =0.47 and 0.53, respectively).Table 2**Patient characteristics at CRRT initiation and outcomesAverage intensity, mL/kg/h\<1010 to 1515 to 20\>20*P*** **-value**Vasopressor use54 (84.4%)92 (66.7%)45 (66.2%)32 (69.6%)0.06Mean arterial pressure, mmHg73 (65, 84)71 (60, 80)73 (64, 83)67 (57, 80)0.23Mechanical ventilation53 (82.8%)111 (80.4%)58 (85.3%)41 (89.1%)0.55PaO~2~/FiO~2~ ratio, Torr215 (152, 300)197 (136, 300)226 (134, 331)208 (125, 336)0.83Lactate, mmol/L2.4 (1.5, 5.7)2.5 (1.4, 5.2)2.4 (1.4, 4.3)3.4 (1.5, 8.0)0.61Glasgow coma scale14 (11, 15)14 (10, 15)14 (9, 15)12 (6, 15)0.05Platelet count, 10^3^/μL107 (59, 163)90 (52, 142)84 (51, 156)88 (56, 154)0.55Bilirubin, mmol/L20.5 (12.0, 54.7)18.8 (10.3, 37.6)15.4 (8.6, 40.6)17.7 (8.6, 42.3)0.26Diuretics use36 (56.3%)62 (44.9%)29 (42.7%)15 (28.3%)0.035Urine output, mL/h17 (5, 45)21 (9, 40)22 (9, 53)16 (5, 42)0.67Creatinine, μmol/L248 (159, 378)242 (182, 328)225 (163, 310)254 (169, 363)0.55Urea, mmol/L18.0 (11.7, 27)17.7 (12.1, 25.8)17.5 (10.7, 23.0)20.0 (14.3, 35.3)0.14ICU to start, day0.9 (0.2, 1.7)0.9 (0.2, 2.0)1.0 (0.2, 2.2)0.4 (0.1, 1.7)0.44Mode of CRRT  CVVH6 (9.4%)7 (5.1%)1 (1.5%)4 (8.7%)0.19  CVVHD24 (37.5%)33 (23.9%)9 (13.2%)8 (17.4%)0.008  CVVHDF34 (53.1%)98 (71.0%)58 (85.3%)34 (73.9%)0.0008Blood flow, mL/min100 (80, 100)100 (80, 100)100 (80, 100)100 (80, 100)0.89CRRT dose, L/h0.60 (0.60, 0.80)0.80 (0.60, 0.8)1.0 (0.8, 1.0)1.3 (1.0, 3.0)\<0.0001Average intensity, mL/kg/h8.7 (7.1, 9.2)12.6 (11.1, 13.9)16.6 (15.7, 18.3)24.4 (20.9, 30.9)\<0.0001CRRT down time (%)5.8 (0, 21.3)1.5 (0, 6.2)2.6 (0.4, 5.2)1.5 (0, 4.0)0.014CRRT duration, days3.9 (1.9, 6.9)3.3 (1.7, 6.1)2.7 (1.7, 5.6)2.6 (1.3, 4.8)0.36ICU mortality30 (46.9%)57 (41.3%)24 (35.3%)22 (47.8%)0.47Hospital mortality35 (54.7%)76 (55.1%)35 (51.5%)30 (65.2%)0.53RRT at discharge among survivors7 (24.1%)6 (9.7%)3 (9.1%)0 (0%)0.09Results are presented as number (%) or median (IQR), ICU to start, duration between ICU admission to continuous renal replacement therapy (CRRT) initiation; CVVH, continuous veno-venous hemofiltration; CVVHD: continuous veno-venous hemodialysis; CVVHDF, continuous veno-venous hemodiafiltration; RRT, renal replacement therapy.

Figure [1](#Fig1){ref-type="fig"} shows relative changes in serum creatinine (1a) and urea (1b) levels in the four groups over the first 7 days of CRRT. The decreases in creatinine and urea increased as the average intensity increased. The relative changes of serum creatinine and urea levels remained close to 1 over the 7 days in the \<10 group.Figure 1**Relationship between the average continuous renal replacement therapy (CRRT) intensity and relative changes in creatinine (a) and urea (b) over seven days from the start of CRRT.** Patients were grouped on the basis of the average intensity (patients) and daily intensity (daily observations) as follows: below 10 (\<10), 10 to 15 (10-15), 15 to 20 (15-20), and above (\>20) mL/kg/h.

During the study period, a total of 1,101 daily observations were conducted in 339 patients. These observations were divided into four groups according to the daily CRRT intensity (\<10, 10 to 15, 15 to 20, and \>20). The groups comprised 254 (23.1%), 470 (42.7%), 239 (21.7%), and 138 observations (12.5%), respectively. Figure [2](#Fig2){ref-type="fig"} shows the daily changes of serum creatinine (2a) and urea (2b) levels in the four groups. Creatinine and urea increased (negative daily change) only in the \<10 group and decreased with the increasing daily intensity in the other groups.Figure 2**Relationship between daily continuous renal replacement therapy (CRRT) intensity and daily changes of creatinine (a) and urea (b).** Patients were grouped on the basis of the average intensity (patients) and daily intensity (daily observations) as follows: below 10 (\<10), 10 to 15 (10-15), 15 to 20 (15-20), and above (\>20) mL/kg/h.

The analyses shown in Figures [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"} were repeated for patients who had sepsis/septic shock (n =151 for average intensity and n =665 for daily intensity) for sensitivity analysis. Findings of these analyses are essentially similar to the analyses for all patients (only intensity \<10 ml/kg/h had poor control for urea and creatinine).

Discussion {#Sec8}
==========

Key findings {#Sec9}
------------

In this study, we have evaluated the impact of different delivered intensities of CRRT on the control of serum creatinine and urea in critically ill patients with severe AKI. We analyzed CRRT intensity by two different definitions: daily intensity and average intensity. Both analyses found that the lower limit of intensity necessary to control uremia during CRRT was approximately between 10 and 15 mL/kg/h in our cohort.

Relationship to previous studies {#Sec10}
--------------------------------

Many studies have been conducted in an attempt to improve the outcome of AKI patients in the ICU \[[@CR7],[@CR9],[@CR10],[@CR23]-[@CR31]\]. Increasing the CRRT intensity is one of the methods used, and several studies have noted the effects of high intensity CRRT \[[@CR7],[@CR9],[@CR10],[@CR14],[@CR15],[@CR29]\]. However, two large randomized controlled trials demonstrated that there was no survival advantage to the use of high-intensity therapy (\>35 mL/kg/h) compared with lower intensity (20 to 25 ml/kg/h) \[[@CR7],[@CR9]\]. Two recent meta-analyses have also shown similar results \[[@CR28],[@CR29]\]. According to these results, the recent KDIGO Clinical Practice Guideline recommended delivering an effluent volume of 20 to 25 ml/kg/h. They also recommended prescribing in the range of 25 to 30 ml/kg/h in order to achieve a delivered dose of 20 to 25 ml/kg/h. \[[@CR11]\]. However, although current evidence seems adequate for recommending the upper limit of CRRT intensity, only limited information is available to support the lower intensity limit. Indeed, there has been no randomized controlled study comparing CRRT intensity lower than 20 to 25 ml/kg/h and only a few observational studies have looked at this issue \[[@CR12],[@CR13],[@CR28]\]. For example, in our previous study \[[@CR13]\], we compared high- and low-intensity therapy using our database (JSEPTIC) and the Beginning and Ending Supportive Therapy for the Kidney (BEST kidney) database \[[@CR2]\]. Although CRRT intensity was lower in our database (14.3 mL/kg/h) compared with that of the BEST kidney database (20.4 mL/kg/h, *P* \<0.001), patients in the JSEPTIC database tended to have lower hospital mortality (58.6% versus 64.2%, *P* =0.070) compared with the BEST study.

As the one of aims of performing CRRT is to control uremia, low-intensity therapy may be thought inadequate and unacceptable when low molecular-weight solutes increase during CRRT. Urea and creatinine, clinically measured low molecular-weight solutes, are commonly used as surrogate markers for the toxic metabolites of renal failure. However, no previous studies have evaluated the impact of different CRRT intensity on controlling uremia. In Japan, replacement/dialysis fluid use of only 10 to 16 mL/kg/h (15 to 24 L/day) is allowed because of the Japanese medical insurance system. Therefore, using our database collected in 14 Japanese ICUs, we studied for relationship between different CRRT intensity and serum creatinine/urea control. As this is a retrospective study and the CRRT dose could have changed every day according to patient conditions, we evaluated the effect of CRRT intensity by two different definitions: daily intensity and average intensity. Both analyses found that creatinine and urea increased only in the \<10 group and decreased with the increasing intensity in the other groups. From our findings, delivered CRRT intensity of around 10 to 15 mL/kg/h seems to be the lower limit to control uremia.

Significance and implications {#Sec11}
-----------------------------

Conducting CRRT is not without complications. Unnecessarily high-intensity CRRT could lead to electrolyte abnormalities such as hypophosphatemia and hypomagnesemia, frequent machine troubles, and inadequate drug administration, especially antibiotics. Therefore, seeking the lower limit of CRRT intensity seems clinically important.

Furthermore, the advantage of lower intensity CRRT is also related to the economic problem of CRRT. It is reported that the cost of CRRT is higher than that of intermittent hemodialysis (IHD) \[[@CR32]\], and the cost of higher-intensity CRRT is more than that of lower-intensity CRRT because of the greater volume of replacement/dialysis fluid required \[[@CR33],[@CR34]\]. This high cost can have a major impact, particularly on low- or middle-income countries.

Strengths and limitations {#Sec12}
-------------------------

There are several strengths in this study. As far as we know, this is the first study to evaluate the effect of different CRRT intensity on solute control. We were able to conduct such an evaluation because it is common to perform low-dose CRRT in Japan and we rarely see difficulty in small solute control in our patients with severe AKI requiring CRRT. Another strength of this study is that we collected information for each filter and evaluated the delivered dose of CRRT, not the prescribed dose. In clinical practice, delivery usually falls substantially short of the prescribed dose. Although it has been reported that on average the delivered dose is approximately 80% of the prescribed dose \[[@CR10],[@CR21]\], such a shortfall can be quite varied day to day and among patients. Using the delivered dose in our study should provide more accurate evaluation of the effect on daily solute control.

There are also several limitations to our study. First, this is a retrospective observational study with a relatively small sample size, which inevitably contains various biases, including differences in patient background and decision-making about prescribed CRRT intensity by a treating physician. For example, it is likely that the CRRT dose was often prescribed regardless of patient body weight. Also, in many cases, the CRRT intensity was between 10 and 15 mL/kg/h because of the Japanese medical insurance system. This resulted in a smaller number (approximately one third) of patients in the higher-intensity group (\>20 mL/kg/h) compared with that in the lower-intensity groups (10 to 15 mL/kg/h). Second, the CRRT intensity was calculated using body weight measured or estimated at ICU admission based on methods that differed between the participating centers. The accuracy of body weight measurements may also have been affected by patient's condition before ICU admission, such as differences in fluid balance and protein catabolism. Third, serum creatinine and urea levels depend on the balance between the body's production, amount of fluid balance/hemodilution and clearance by CRRT and the kidneys. We did not collect information on small solute clearance from residual kidney function and daily body fluid balance, and therefore, we might have overestimated (or underestimated) creatinine/urea changes at some time points or in some patients. Finally, and most importantly, we did not evaluate the relationship between CRRT intensity and mortality/morbidity, such as renal recovery, weaning of vasopressors and mechanical ventilation, ICU and hospital length of stay. With all the limitations and drawbacks of this study, we cannot recommend to the ICU medical community to routinely use 10 to 15 mg/kg/h.

Conclusions {#Sec13}
===========

In this study for the first time in the literature, we have evaluated the impact of different intensities of CRRT on the control of serum creatinine and urea in critically ill patients with severe AKI. We found that the lower limit of intensity to control uremia during CRRT was approximately between 10 and 15 mL/kg/h in our cohort. A prescribed intensity of approximately 15 mL/kg/h might be adequate to control uremia for patients with severe AKI in the ICU. This issue is important to avoid side effects of CRRT and reduce costs, particularly in low- or middle-income countries. However, considering the limitations due to the retrospective nature of this study, prospective studies are required to confirm our findings.

Key messages {#Sec14}
============

The lower limit of intensity to control uremia during CRRT seemed to be approximately between 10 and 15 mL/kg/hA prescribed intensity of approximately 15 mL/kg/h might be adequate to control uremia for patients with severe AKI in the ICUTo determine the lower limit of intensity to control uremia during CRRT is important to avoid side effects of CRRT and reduce costs, particularly in low- or middle-income countries
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